Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Errata
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631559/
https://www.ncbi.nlm.nih.gov/pubmed/35723890
http://dx.doi.org/10.1182/bloodadvances.2022007724
_version_ 1784823838965497856
collection PubMed
description
format Online
Article
Text
id pubmed-9631559
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-96315592022-11-04 Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094. Blood Adv Errata American Society of Hematology 2022-06-20 /pmc/articles/PMC9631559/ /pubmed/35723890 http://dx.doi.org/10.1182/bloodadvances.2022007724 Text en © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
spellingShingle Errata
Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
title Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
title_full Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
title_fullStr Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
title_full_unstemmed Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
title_short Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.
title_sort lissitchkov t, willemze a, katragadda s, et al. efanesoctocog alfa for hemophilia a: results from a phase 1 repeat-dose study. blood adv. 2022;6(4):1089-1094.
topic Errata
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631559/
https://www.ncbi.nlm.nih.gov/pubmed/35723890
http://dx.doi.org/10.1182/bloodadvances.2022007724

Ejemplares similares